Table 5.
Patients ORa (95% CI) |
Controls ORb (95% CI) |
|
---|---|---|
Age | ||
Continuous | 1.02 (0.97, 1.09) | 1.00 (0.95, 1.05) |
Race | ||
African-American | 4.02 (1.57, 10.28) | 2.40 (1.00, 5.03) |
White | Reference | Reference |
Marital status | ||
Married/partnered | 0.98 (0.40, 2.40) | 1.07 (0.51, 2.24) |
Not married/partnered | Reference | Reference |
Socioeconomic Status | ||
<$50,000 income, ≤HS graduate | 1.43 (0.46, 4.42) | 2.22 (0.76, 6.48) |
<$50,000 income, >HS graduate | 0.77 (0.28, 2.08) | 1.75 (0.61, 4.99) |
≥$50,000 income | Reference | Reference |
Insurance status | ||
Public/uninsured/unknown | 4.76 (1.34, 12.38) | 1.75 (0.61, 4.99) |
Private | Reference | Reference |
Vitality Score | ||
Below median | 5.71 (2.48, 13.15) | 2.38 (1.21, 4.68) |
At or above median | Reference | Reference |
Comorbidity | ||
2+ | 0.75 (0.22, 2.59) | 1.56 (0.50, 4.86) |
1 | 0.96 (0.39, 2.40) | 0.84 (0.37, 1.93) |
None | Reference | Reference |
Social support | ||
Continuous | 1.00 (0.55, 1.82) | 1.24 (0.81, 1.90) |
Treatment during study | ||
Surgery + chemotherapy + radiation | 1.62 (0.58, 4.51) | |
Surgery + radiation | 0.99 (0.41, 2.42) | |
Surgery + chemotherapy | 1.47 (0.36, 6.05) | |
Surgery only | Reference | |
Endocrine therapy during study | ||
Yes | 0.62 (0.29, 1.33) | |
No | Reference |
Adjusted for age, race, marital status, socioeconomic status, insurance status, vitality score, comorbidity, social support, treatment type, and endocrine therapy during study. Bold type indicates statistical significance.
Adjusted for age, race, marital status, socioeconomic status, insurance status, vitality score, comorbidity, and social support. Bold type indicates statistical significance.